In conclusion, this study demonstrates that uptake of the anti-PD-L1 tracer 18F-BMS-986192 in spleen, especially in NSCLC, might be a potential predictive biomarker for response to ICI treatment, possibly related to the presence of MRCs. The gene discussed is CD274; the disease is non-small cell lung carcinoma.